Oct. 12 (Wed.) ,2016 13:30-14:30

Annex Hall

Simultaneous Interpretation

British Embassy Department of International Trad

Regenerative Medicine in the UK: A Rich and Diverse Ecosystem to Accelerate Commercialisation

To accelerate commercialisation of Regenerative Medicine, the British Government has actively implemented a wide range of activities including establishment of “Cell and Gene Therapy Catapult” in 2012 and the UK Regenerative Medicine Platform in 2013. The UK has world-class academia/research institutes, attracts talented people, and provides a rich diverse ecosystem. In the UK, we also see active companies in this field. In this seminar, we will present “How the UK facilitates translating/commercialising Regenerative Medicine R&D”. Strategies /roles of academia and Cell and Gene Therapy Catapult, collaborations with the industry and case studies of some spin-out companies and business opportunities in the UK will be introduced. We will also touch on our commercial support to Japanese companies through collaborations with UK partners. We will also introduce two UK companies (Plasticell Ltd and Videregen Limited) who are actively developing their businesses.

UK and International Partnerships to Solve Translational and Commercial Barriers in Regenerative Medicine

Kevin Shakesheff

Pro-Vice Chancellor of the Faculty of Science/Director of UK Regenerative Medicine Hub in Acellular Materials, University of Nottingham

Catapults: Driving Cell and Gene Therapy Innovation

Michael Bennett

Head of Transaction and Intellectual Property, Cell and Gene Therapy Catapult

Steve Bloor

CEO, Videregen Limited

Dennis Saw

CEO, Plasticell

Close Window